Loading...

Top
Help
×

By creating an account you can:

Logo TaxTMI
Call Us / Help / Feedback

Contact Us At :

E-mail: [email protected]

Call / WhatsApp at: +91 99117 96707

For more information, Check Contact Us

FAQs :

To know Frequently Asked Questions, Check FAQs

Most Asked Video Tutorials :

For more tutorials, Check Video Tutorials

Submit Feedback/Suggestion :

Email :
Please provide your email address so we can follow up on your feedback.
Category :
Description :
Min 15 characters 0/2000
Make Most of Text Search
  1. Checkout this video tutorial: How to search effectively on TaxTMI.
  2. Put words in double quotes for exact word search, eg: "income tax"
  3. Avoid noise words such as : 'and, of, the, a'
  4. Sort by Relevance to get the most relevant document.
  5. Press Enter to add multiple terms/multiple phrases, and then click on Search to Search.
  6. Text Search
  7. The system will try to fetch results that contains ALL your words.
  8. Once you add keywords, you'll see a new 'Search In' filter that makes your results even more precise.
  9. Text Search
Add to...
You have not created any category. Kindly create one to bookmark this item!
Create New Category
Hide
Title :
Description :
❮❮ Hide
Default View
Expand ❯❯
Close ✕
🔎 News - Adv. Search
TEXT SEARCH:

Press 'Enter' to add multiple search terms. Rules for Better Search

Search In:
Main Text + AI Text
  • Main Text
  • Main Text + AI Text
  • AI Text
Category: ?
Categorized by AI
---- All Categories ----
  • ---- All Categories ----
  • Income Tax
  • GST
  • Customs, DGFT & SEZ
  • FEMA & RBI
  • Corp. Laws, SEBI & IBC
  • PMLA, Black Money & ED
  • Budget
  • News and Press Release
  • PTI News
Month:
---- All Months ----
  • ---- All Months ----
  • January
  • February
  • March
  • April
  • May
  • June
  • July
  • August
  • September
  • October
  • November
  • December
Year:
---- All Years ----
  • ---- All Years ----
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
Sort By: ?
In Sort By 'Default', exact matches for text search are shown at the top, followed by the remaining results in their regular order.
Relevance Default Date
❯❯
Maximize Maximize Maximize
0 / 200
Expand Note
Add to Folder

No Folders have been created

+

Are you sure you want to delete "My most important" ?

NOTE:

News
Showing Results for :
Reset Filters
Results Found:
Show All Summaries Hide All Summaries
April 4, 2026
Show AI Summary
Bribery allegations against a CGST officer trigger a CBI trap, arrest, and continuing investigation into corruption claims.
Bribery allegations led to a CBI trap and arrest of an Assistant Commissioner, CGST, Ratlam, after a private person or middleman allegedly demanded money for not initiating GST proceedings against the complainant's firm. The accused was caught red-handed while accepting a bribe through the middleman, with searches continuing at the accused's premises and investigation still in progress.
April 4, 2026
Show AI Summary
Mutual fund approval process for subscribing to eligible public issues under the Income-tax Act framework clarified.
Approval is sought by a mutual fund to subscribe to an eligible issue of public companies under Schedule XV(1)(z)(ii) of the Income-tax Act, 2025, through Form 190. The form must be filed three months before the issue of eligible capital with the prescribed details and documents, including mutual fund and management particulars, scheme details, SEBI and custodian records, audited financial statements, and approval documents relating to the public company's share issue.
April 4, 2026
Show AI Summary
Mutual fund approval for eligible public company issues depends on timely filing of Form 190.
A mutual fund must file Form 190 to seek approval for investment in the eligible issue of public companies under Schedule XV(1)(z)(ii) of the Income-tax Act, 2025. The form corresponds to the earlier Form 59A under the Income-tax Rules, 1962, and to the corresponding rule framework under the Income-tax Rules, 2026. The application is to be filed by the mutual fund itself, together with the documents specified in the form, three months before the issue of eligible capital. Approval for subscription is granted on the basis of the particulars furnished in Form 190.
April 4, 2026
Show AI Summary
Approval for issue of eligible capital under Schedule XV depends on Form 189 details, disclosures, and supporting documents.
Form 189 is the application for approval of issue of public companies under Schedule XV(1)(z)(i) of the Income-tax Act, 2025, and is filed by the public company three months before the issue of eligible capital. The form requires company particulars, management details, bankers and auditors, issue details, project details, and supporting documents such as incorporation certificate, audited financial statements, equity details, SEBI approval and any project report. Processed Form 189 leads to approval for issue of eligible capital on the basis of the details furnished.
April 4, 2026
Show AI Summary
Public company issue approval through Form 189 governs eligible capital issues and related deduction eligibility.
Form 189 is the prescribed application for approval of issue of public companies under Schedule XV(1)(z)(i) of the Income-tax Act, 2025. It is filed by the public company with supporting documents before the issue of eligible capital, and the approval is granted on the basis of the details furnished in the form. Individual contributions to the issue are stated to qualify for deduction under the Act.
April 4, 2026
Show AI Summary
Consolidated approval form standardises gratuity and superannuation fund compliance, replacing rule-based particulars with structured filing.
Introduction of consolidated Form 188 standardises the approval process for Gratuity Fund and Superannuation Fund applications under Part B of Schedule XI by replacing the earlier text-based particulars in Rule 95 and Rule 109. The form is filed by trustees or an authorised person only for initial approval, and it requires details of the employer, the fund, eligible employees, account maintenance, fund status, trustee verification, and supporting documents such as the trust deed, fund rules, and accounts where applicable.
April 4, 2026
Show AI Summary
Approval mechanism for gratuity and superannuation funds is standardised through Form 188 with structured compliance requirements.
Form 188 provides a standardised application mechanism for approval of Gratuity Funds and Superannuation Funds, replacing earlier rule-based procedural requirements. It is filed once by the trustees or an authorised person, with prescribed particulars and supporting documents such as the trust deed, fund rules, accounts, and balance sheet where applicable. The application is examined by the jurisdictional authority, which may seek clarifications and then grant approval, issue deficiency notice, or reject the application.
April 4, 2026
Show AI Summary
Appeal against fund recognition refusal uses Form 187, with supporting documents and filing within 60 days.
Appeal against refusal to recognise or withdrawal of recognition from a recognised provident fund, and refusal to approve or withdrawal of approval from a superannuation fund or gratuity fund, is filed in Form 187 by the employer, trustee, or authorised representative within 60 days of communication of the order. The form requires appellant particulars, fund details, grounds of appeal, verification, and supporting documents such as the impugned order, original application, proof of filing, authorisation, and fee challan.
April 4, 2026
Show AI Summary
Appeals for provident, superannuation and gratuity funds require Form 187, supporting documents and filing within 60 days.
Form 187 prescribes the appellate mechanism under the Income-tax Act, 2025 for matters concerning recognised provident funds, superannuation funds and approved gratuity funds, including appeals against orders affecting recognition, approval, withdrawal, cancellation or refusal of such status. The form is to be used by trustees, employers or other authorised persons representing the fund where an adverse order has been passed by the competent income-tax authority. Appeals must be filed within 60 days from communication of the order, and filing does not by itself operate as a stay unless specifically granted.
April 4, 2026
Show AI Summary
Customs enforcement along the India-Nepal border led to seizure of undocumented soft drinks and air conditioners.
Customs enforcement along the India-Nepal border led to seizure of soft drinks and air conditioners being moved without valid customs documents. A vehicle carrying 1,575 bottles of soft drinks was intercepted after the driver tried to flee, while two split air conditioners transported on bicycles were also recovered in a separate patrol operation. The goods, vehicle and bicycles were handed over to the Customs Department.
April 4, 2026
Show AI Summary
Indian pharmaceutical exports show sustained growth as formulations, biologicals, vaccines and Ayush products drive resilience.
Indian pharmaceutical exports recorded sustained growth in FY26, reaching nearly USD 29 billion by the end of February and increasing over the corresponding period in the previous financial year. The export performance was led by formulations, biologicals, vaccines and Ayush products, and was described as resilient despite global challenges, pricing pressures and trade volatility. The sector's overall value was placed at about USD 60 billion, with projected expansion to USD 130 billion by 2030.
April 4, 2026
Show AI Summary
Recognised Provident Fund recognition process requires trust deed compliance, supporting documents, scrutiny and ongoing investment and reporting obligations.
Application under Rule 40C seeks recognition of a provident fund so it qualifies as a Recognised Provident Fund for income-tax purposes. It applies to employers, trustees and existing funds seeking recognition on formation, conversion, amendment, merger or split. The form requires trust deed details, fund rules, investment policy, financial information and supporting documents, followed by scrutiny, possible revisions, issuance of recognition and ongoing compliance with investment, audit and reporting requirements.
April 4, 2026
Show AI Summary
Recognised Provident Fund recognition through Form 186 depends on disclosure, supporting documents, and compliance with trust conditions.
Form 186 is the prescribed application for seeking recognition of a provident fund as a Recognised Provident Fund for income-tax purposes. It is filed by the employer, trustees, or an existing trust seeking recognition, and is ordinarily a one-time application subject to refiling or intimation for material changes in the trust deed or fund rules. The form requires detailed disclosures and supporting documents, and on approval the fund attains RPF status with tax treatment governed by applicable statutory limits and conditions. Recognition may later be withdrawn for non-compliance.
April 4, 2026
Show AI Summary
Recognised provident fund accounting in Form 185 requires annual subscriber-wise records of contributions, interest, withdrawals, and balances.
Rule 294 requires recognised provident fund accounts to be prepared at intervals not exceeding twelve months, with a separate account maintained for each subscriber in Form 185. The form is maintained internally by the provident fund trust or authorised officers, and records subscriber particulars, opening balance, monthly contributions, interest, withdrawals or advances, closing balance, and verification. Part A is maintained separately for each subscriber, while Part B presents the same information in consolidated annual subscriber-wise form.
April 4, 2026
Show AI Summary
Recognised Provident Fund recordkeeping requires Form 185 to track contributions, interest, withdrawals, and annual balances.
Form No. 185 is the prescribed accounting format for individual subscriber records under a Recognised Provident Fund, maintained by trustees or authorised officers under the Income-tax Rules. It records annual subscriber-wise particulars such as contributions, interest credited, withdrawals or advances, opening and closing balances, and verification details. Part-A is kept for each subscriber, while Part-B is the annual consolidated abstract filed with the Assessing Officer.
April 4, 2026
Show AI Summary
Deduction audit report for petroleum and natural gas businesses requires deposit verification, withdrawal checks, and Chartered Accountant certification.
Form No. 183 is the prescribed audit report for claiming deduction under section 49 in the business of prospecting, extracting, or producing petroleum, natural gas, or both in India. It is furnished by a Chartered Accountant and verifies audit of the relevant books, timely deposit into the specified account, permitted use of withdrawals, disallowance of inadmissible expenditure, and transfer restrictions on assets acquired under the scheme. The form is filed annually before the return due date and requires supporting records of books, deposits, withdrawals, and asset transfers.
April 4, 2026
Show AI Summary
Supply chain disruption hits Bikaner snack exports as conflict delays shipments and raises freight and input costs.
West Asia conflict has disrupted Bikaner exports and imports, causing delays in shipments of bhujia, papad, namkeen and spices to Gulf and European markets. Traders report longer transit routes, container shortages, higher freight charges, rising raw material and packaging costs, and consignments stuck at ports or in transit, affecting the city's export-driven economy.
April 4, 2026
Show AI Summary
Audit report for petroleum and natural gas deduction claims requires certification, supporting records, and online filing compliance.
Form No. 183 is the prescribed audit report under Rule 291 read with Section 49 of the Income-tax Act, 2025 for an assessee engaged in the business of prospecting, extracting, or producing petroleum, natural gas, or both in India. It is mandatory where the deduction is claimed and must be certified by an Accountant. The form requires supporting books, financial statements, evidence of deposits and withdrawals from the specified account, and a computation showing that the deduction remains within the permissible limit.
April 4, 2026
Show AI Summary
Deduction claim audit report for tea, coffee and rubber businesses requires Chartered Accountant certification and compliance with deposit rules.
Form No. 182 is a statutory audit report for assessees engaged in growing and manufacturing tea, coffee or rubber who claim deduction under section 48. It must be furnished by a Chartered Accountant annually before the return due date and certifies audit of books, timely deposit in the specified account or approved scheme, withdrawal utilisation, disallowable amounts, asset transfers, and the deduction permissible. The form is now a smart, tabulated e-form with mandatory professional identifiers and standardised fields for e-filing and validation.
April 4, 2026
Show AI Summary
Tax deduction audit report rules require prescribed certification, verified deposits, and portal filing for tea, coffee and rubber businesses.
Form No. 182 is the prescribed audit report for assessees engaged in growing and manufacturing tea, coffee or rubber in India who claim deduction under section 48. It must be certified by an Accountant and furnished annually before the return due date. The report is mandatory for the deduction claim, supports verification of deposits, withdrawals, utilisation and deduction computation, and is completed through the e-filing portal with digital signing and assessee acceptance.

News

Back

All News

Showing Results for :
Reset Filters
No Records Found

News

Back

All News

Showing Results for : Reset Filters
Customs & Trade

Built on Service, Trust and Quality: How Alpex Pharma Became the Manufacturing Partner Pharma Brands Rely On

March 19, 2026

Contents
Summary
Note

Note

-

Bookmark

Print

Print

With a multi-certified, multi-division manufacturing infrastructure and an established presence across domestic and international markets, Alpex Pharma is setting a new benchmark for what third-party pharmaceutical manufacturing should look like in India. INDIA — The Indian pharmaceutical industry stands at a defining moment. Domestic demand is surging, regulatory standards are tightening, and Indian-made medicines are earning growing respect in markets across Asia, Africa, and beyond. At the centre of this transformation is a quiet but powerful engine — the contract manufacturer. And few have positioned themselves for this moment as deliberately, or as decisively, as Alpex Pharma. Under the leadership of Director Shubham Mittal, Alpex Pharma has built a manufacturing organisation that bears none of the hallmarks of a conventional contract facility. It operates with the systems, the certifications, the infrastructure, and the service philosophy of an enterprise that was designed from the outset to support pharma brands at scale — domestically and globally. A Manufacturing Organisation Built for Regulated Markets At the foundation of Alpex Pharma’s operations is a quality infrastructure that meets and exceeds the standards of the world’s most demanding pharmaceutical regulatory frameworks. The company holds WHO-GMP, GMP, GLP, and Ghana-GMP certifications — the gold standard combination for manufacturers supplying both India’s domestic market and regulated international markets. The addition of Ghana-GMP accreditation signals something beyond compliance. It reflects a strategic commitment to international manufacturing standards and demonstrates that Alpex Pharma’s quality systems have been independently verified against the requirements of export-destination regulators — not just domestic ones. For brand partners with global ambitions, this distinction matters enormously. Global Reach Through Strategic Partnerships Alpex Pharma enables pharma brands to access international markets through established neutral code manufacturing partnerships — producing under partner brand identities across multiple geographies. This infrastructure allows brand owners to expand globally without the capital investment of building their own international supply chain. Specialist Divisions. Enterprise-Grade Separation. One of the clearest indicators of a manufacturer’s true capability is not its equipment list — it is how it organises itself. Alpex Pharma operates across three dedicated, fully separated manufacturing divisions, each purpose-built for its product category with the infrastructure, containment protocols, and compliance architecture it demands. • General Division : Tablets, capsules across a broad therapeutic range, serving domestic and export markets with full GMP compliance. • Beta-Lactam Division : Dedicated Beta-Lactam manufacturing with full containment, regulatory separation and specialist protocols for sensitive antibiotic classes. • Cephalosporin Division : Isolated Cephalosporin production infrastructure meeting the highest standards of cross-contamination prevention and regulatory compliance. This level of divisional separation is not common among Indian contract manufacturers. It reflects an investment in doing things properly — the kind of structural commitment that enterprise pharma clients, institutional buyers, and international regulators look for when evaluating a manufacturing partner for the long term. “Quality is not a stage in our production process. It is the architecture of eveAlpexng we build — every division, every system, every client relationship.” — Shubham Mittal, Director, Alpex Pharma The Standard That Sets Alpex Pharma Apart What distinguishes Alpex Pharma in a crowded contract manufacturing landscape is not any single certification or facility specification. It is the consistent experience of every brand that works with the company — an experience defined by reliability, transparency, and a service culture that treats each client’s business as seriously as its own. Alpex Pharma’s account management model is built on dedicated partnerships. Brand owners are not passed between teams or managed through a generic helpdesk. They work with a dedicated team that understands their product portfolio, their market, their regulatory requirements, and their commercial timelines — and is accountable for all of it. Production scheduling is built around the client’s launch windows and distribution cycles. And delivery commitments, once made, are treated as non-negotiable. This is the operational definition of service, trust and quality — not as corporate values on a wall, but as the daily practice of a manufacturing organisation that has built its entire reputation on them. It is also precisely why Alpex Pharma has become the top third-party manufacturer of choice for pharma brands across India and international markets. “We do not want to be the largest manufacturer in the room. We want to be the most trusteAlpex PharmaIndia’s that every brand in our portfolio would recommend without hesitation.” — Shubham Mittal, Director, Alpex Pharma India’s Pharma Ambition Needs Partners Like This India’s contract manufacturing sector is undergoing a generational shift. The brands emerging from this market are more sophisticated, more globally ambitious, and more discerning about their supply chain partners than any previous generation. They are not looking for the cheapest option. They are looking for the most reliable one — a manufacturing partner whose quality systems, international credentials, service culture, and operational discipline can match their own ambitions and protect their brand as they grow. Alpex Pharma has positioned itself squarely in that space. Not as a commodity contract manufacturer competing on price, but as a quality-led enterprise competing on performance. With internationally recognised certifications, enterprise-grade divisional infrastructure, established global export pathways, and a service philosophy rooted in genuine partnership, the company represents a new standard for what third-party pharmaceutical manufacturing can and should be in India. The pharmaceutical brands that choose Alpex Pharma are not simply outsourcing production. They are gaining a manufacturing partner with the capability, the credentials, and the commitment to grow with them — wherever that growth takes them. About Alpex Pharma Alpex Pharma is a leading third-party pharmaceutical manufacturer based in India, holding WHO-GMP, GMP, GLP, and Ghana-GMP certifications. Operating across three specialist divisions — General, Beta-Lactam, and Cephalosporin — the company serves pharma brands in domestic and international markets with a commitment to quality, reliability, and partnership. For more information, visit www.alpexpharma.in. Media Contact Alpex Pharma — Communications Email: [email protected] Website: www.alpexpharma.in (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI PWR

Topics

Acts Income Tax